ZeroHarm Sciences, a company specializing in nano-formulated, plant-based nutraceuticals, has successfully closed a Series A funding round, securing $7.15 million (Rs 65 crore). This investment is spearheaded by Kotak Alternate Asset Managers Limited, contributing Rs 40 crore through its Kotak Life Sciences Fund I, with Alkemi Growth Capital adding Rs 25 crore. The infusion of capital will fuel ZeroHarm’s strategic initiatives, including strengthening its brand presence nationwide, expanding its international footprint across key markets such as the USA, the UK, and the Middle East, and enhancing its research and manufacturing capabilities. Founded in 2020 by Sachin and Shweta Darbarwar, ZeroHarm Sciences is dedicated to the development of plant-based health supplements, leveraging proprietary nano-formulation technology. The company is committed to establishing India’s first ‘Trust over Promise’ health platform, aiming to validate supplement efficacy through quantifiable consumer health outcomes.
Operating from Hyderabad, ZeroHarm Sciences employs a unique process of converting plant-based nutrients into nano-sized particles. This innovative approach enhances bioavailability and enables controlled release at lower dosages, effectively merging traditional Ayurveda principles with advanced technology to deliver preventive wellness solutions. The company maintains tight control over its value chain, sourcing medicinal plants from a network of over 10,000 farmers located in Northeast India and the Himalayas. ZeroHarm Sciences has secured patents for its nano-formulations, which cover a range of applications, including turmeric-based phytochemicals, iron folic acid combinations, carotenoid-based eye health solutions, and synbiotic gut health compositions. The company’s product portfolio includes over 60 SKUs, addressing various health needs such as diabetes management, heart health, joint care, immunity enhancement, gut health, oncology support, women’s wellness, and performance nutrition.
These products are accessible to consumers through the company’s website, as well as major e-commerce platforms like Amazon and Flipkart, and quick commerce platforms. To date, the brand has served more than 300,000 customers. The Indian nutraceutical market is projected to reach $18 billion by 2025, while the global market is expected to exceed $720 billion by 2027. ZeroHarm Sciences faces competition from other players in the nutraceutical space, including Kapiva, Plix, HealthKart, and Wellbeing Nutrition. ZeroHarm’s approach integrates traditional medicine with cutting-edge science, which positions the company uniquely in the rapidly growing nutraceuticals market.
The company’s reliance on nano-formulation technology to boost nutrient absorption and controlled release could give it a competitive edge, potentially leading to more effective products and better consumer outcomes. The company’s claim to build India’s first ‘Trust over Promise’ health platform signals an intent to enhance transparency and accountability in the nutraceutical sector, where product efficacy is a constant concern for consumers. Securing patents for its formulations not only protects ZeroHarm’s innovations but also strengthens its market position, offering a degree of exclusivity over its products. As the company expands its reach both domestically and internationally, these patents could be crucial in maintaining a competitive advantage and attracting further investment. The Series A funding will be critical in supporting these growth initiatives, enabling ZeroHarm to scale its operations and broaden its product range to meet the increasing demand for scientifically backed nutraceutical solutions.
Moreover, the company’s focus on preventive wellness aligns with the growing consumer trend toward proactive health management, which bodes well for its long-term prospects.
